Zacks Investment Research
10 Jul 2026, 10:46 UTC · 2h ago
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
10 Jul 2026, 10:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Verastem (VSTM) revenues are expected to grow 981.8% year-over-year to $23.15 million in its upcoming quarterly report. — Massive revenue growth is a strong positive signal for a biotech firm's commercial viability and growth prospects.
+0.60Verastem's product, Avmapki Fakzynja Co-Pack, is approved in the US for treating KRAS mutant recurrent low-grade serous ovarian cancer. — FDA approval and market entry for a specialized cancer treatment provide a fundamental catalyst for long-term revenue.
+0.40The consensus EPS estimate for Verastem (VSTM) has been revised 4.8% lower over the last 30 days. — Negative revisions in earnings estimates typically correlate with downward pressure on stock prices.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Shares rallied due to investor confidence in growth prospects of its approved product and pipeline progress, despite lower earnings estimate revisions.
The stock closed higher and has seen a 22.4% return over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
1h ago
